• Users Online: 431
  • Print this page
  • Email this page
Year : 2020  |  Volume : 10  |  Issue : 4  |  Page : 309-311

Cyclosporine 0.1% (Ikervis®) as a corticoid-sparing agent in Lyell syndrome with KeraKlear® keratoprosthesis

Department of Ophthalmology, Hospital Universitari i Politecnic La Fe, Valencia, Spain

Correspondence Address:
Dr. Miriam Rahhal-Ortuno
Calle Hebreísta Pérez Bayer 11, 6-A; Valencia, Postal Code 46002
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/tjo.tjo_1_20

Rights and Permissions

Cyclosporine 0.1% was used in a patient with Lyell syndrome, which had undergone a KeraKlear® keratoprosthesis implant due to the severe ocular involvement to avoid overuse of corticoid agents. To the best of our knowledge, this is the first reported case of cyclosporine 0.1% eye drops to use in Lyell syndrome previously treated with keratoprosthesis implant.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded98    
    Comments [Add]    

Recommend this journal